Geoffrey Shapiro
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Geoffrey Shapiro as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03310879 · Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6Dana-Farber Cancer Institute · recruiting · Cancer · principal investigator
- Ph1NCT03170206 · Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerDana-Farber Cancer Institute · completed · Lung Cancer · principal investigator
- Ph1NCT03065062 · Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsDana-Farber Cancer Institute · suspended · Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer · principal investigator
- Ph1NCT03057145 · Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid TumorsGeoffrey Shapiro, MD, PhD · completed · Solid Tumor · principal investigator
- Ph2NCT02873975 · A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair DeficiencyDana-Farber Cancer Institute · completed · Advanced Cancers · principal investigator
- Ph2NCT02656849 · BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified TumorsDana-Farber Cancer Institute · withdrawn · Solid Tumor · principal investigator
- Ph1NCT02552953 · A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced CancersCyclacel Pharmaceuticals, Inc. · completed · Cancer · principal investigator
- Ph1NCT02022982 · PALBOCICLIB + PD-0325901 for NSCLC & Solid TumorsDana-Farber Cancer Institute · completed · KRAS Mutant Non-Small Cell Lung Cancer, Solid Tumors · principal investigator
- Ph1NCT01664000 · A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid TumorsCellceutix Corporation · completed · Solid Tumors · principal investigator
- Ph1NCT01280487 · A Safety Study of Oral ZSTK474 in Patients With CancerZenyaku Kogyo Co., Ltd. · completed · Neoplasms · principal investigator
- Ph1NCT01011972 · A Study of Intravenous XMT-1107 in Patients With Advanced Solid TumorsMersana Therapeutics · completed · Neoplasm Metastasis · principal investigator
- Ph1NCT00999401 · A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid TumorsCyclacel Pharmaceuticals, Inc. · completed · Advanced Solid Tumors · principal investigator
- Ph1NCT00724100 · A Trial of ALB 109564(a) in Subjects With Advanced Solid TumorsAlbany Molecular Research, Inc. · terminated · Cancer · principal investigator
- Ph1NCT00524524 · An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid TumorsArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · completed · Advanced Solid Tumors · principal investigator
- Ph1NCT00072436 · Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid TumorsNational Cancer Institute (NCI) · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1NCT00007917 · Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph1NCT00070239 · Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic MalignanciesNational Cancer Institute (NCI) · terminated · Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast CancerP50CA168504 · NCI · DANA-FARBER CANCER INST · fiscal years 2021 to 2026 · $2,525,262 awarded in 2026Same name and institution; not confirmed by an ID
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · fiscal years 2014 to 2026 · $2,272,446 awarded in 2026Same name and institution; not confirmed by an ID
- Pathology CoreP01CA269021 · NCI · DANA-FARBER CANCER INST · fiscal years 2024 to 2026 · $411,436 awarded in 2026Same name and institution; not confirmed by an ID
- Program 12: Developmental TherapeuticsP30CA006516 · NCI · DANA-FARBER CANCER INST · fiscal years 2020 to 2026 · $48,206 awarded in 2026Grant number is on one of their registry trials
- Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancersR01CA272982 · NCI · DANA-FARBER CANCER INST · fiscal years 2022 to 2025 · $795,857 awarded in 2025Same name and institution; not confirmed by an ID
- ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)P50CA240243 · NCI · DANA-FARBER CANCER INST · fiscal years 2020 to 2024 · $393,712 awarded in 2024Same name and institution; not confirmed by an ID
- Cyclin-Dependent Kinase Inhibition During S PhaseR01CA090687 · NCI · DANA-FARBER CANCER INST · fiscal years 2001 to 2014 · $296,988 awarded in 2014Same name and institution; not confirmed by an ID
- Translational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · fiscal years 2008 to 2009 · $195,254 awarded in 2009Same name and institution; not confirmed by an ID
- IDENTIFICATION OF CYCLIN C ASSOCIATED PROTEINSK08CA073700 · NCI · DANA-FARBER CANCER INST · fiscal years 1997 to 1998 · $77,061 awarded in 1998Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 1994 to 2013
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:57 UTC. The ranking covers the 200 most relevant of 212 PubMed records, and a shared surname and initials can bring in a namesake. All 212 on PubMed
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med · 20103,653 citationsRCR 86.4
- Crizotinib in ROS1-rearranged non-small-cell lung cancer.N Engl J Med · 20141,567 citationsRCR 42.3
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med · 20201,444 citationsRCR 58.9
- Long-term effects of budesonide or nedocromil in children with asthma.N Engl J Med · 20001,064 citationsRCR 29.5
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol · 20121,021 citationsRCR 26.5
- Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med · 2010685 citationsRCR 16.4
- 650 citationsRCR 20.3
- First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.Cancer Discov · 2013556 citationsRCR 16.1
- Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.J Clin Oncol · 2011512 citationsRCR 11.8
- Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Clin Cancer Res · 2012468 citationsRCR 11.4